Autoimmune Diseases/therapy; Diabetes Complications/classification/therapy; Diabetes Mellitus/therapy; Diabetes Mellitus, Type 1/therapy; Diabetes Mellitus, Type 2/prevention & control/therapy; France; Health Knowledge, Attitudes, Practice; Humans; Public Health
Résumé :
[en] Diabetes mellitus is a chronic disease whose prevalence is increasing worldwide. It remains associated with a high risk of severe complications, essentially micro- and macro-vascular complications. Type 1 diabetes is an auto-immune disease that leads to the destruction of insulin-secreting B cells and therefore requires an intensive optimised exogenous insulin therapy. Type 2 diabetes is a polygenic disease whose expression is favoured by inadequate lifestyle, leading to obesity. It combines a relative insulin secretory defect and insulin resistance, the latter being associated with various other cardiovascular risk factors. Treatment consists of lifestyle modifications first, then the prescription of various glucose-lowering oral drugs and finally, when requested, insulin therapy. A multi-risk intervention is mandatory to improve the cardiovascular prognosis. The prevention of diabetes and its complications is a major public health objective.
Disciplines :
Endocrinologie, métabolisme & nutrition
Auteur, co-auteur :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Langue du document :
Français
Titre :
Le diabete: de la connaissance clinique a la preoccupation de sante publique.
Titre traduit :
[en] Diabetes mellitus: from clinical knowledge to public health concern
Daneman D., Type 1 diabetes, Lancet, 2006, 367, 847-858.
Drucker D. J. & Nauck M. A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
Eckel R. H., Grundy S. M. & Zimmet P. Z., The metabolic syndrome. Lancet, 2005, 365, 1415-1428.
Eisenbarth G. S., Type 1 diabetes. A chronic autoimmune disease, N. Engl. J. Med., 1986, 314, 1360-1368.
Gale E. A. M., Declassifying diabetes. Diabetologia, 2006, 49, 1989-1995.
Grimaldi A., Éditeur, Traité de Diabétologie, Médecine-Sciences Flammarion, Paris, France, 2005.
Hirsch I. B., Insulin analogues. New Engl. J. Med., 2005, 352, 174-183.
Kahn S. E., The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia, 2003, 46, 3-19.
Krentz A. J. & Bailey C. J., Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, 65, 385-411.
Lindstrom J., Ilanne-Parikka P., Peltonen M. et al. & Finnish Diabetes Prevention Study Group, Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet, 2006, 368, 1673-1679.
Nathan D. M., Buse J. B., Davidson M. B. et al., Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006, 29, 1963-1972
et Diabetologia, 2006, 49, 1711-1721.
Radermecker R. P. & Scheen A. J., Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes/Metab. Res. Rev., 2004, 20, 178-188.
Scheen A. J., Current management of coexisting obesity and type 2 diabetes. Drugs, 2003, 63, 1165-1184.
Scheen A. J., Antidiabetic agents in patients with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab., 2007, 33, 3-12.
Scheen A. J. & Lefèbvre P. J., Insulin resistance vs insulin deficiency: which comes first? The old question revisited, In : Diabetes in the New Millennium (Di Mario U., Leonetti F., Pugliese G., Sbraccia P. & Signore A., Eds), J. Wiley & Sons, New York, 2000, 101-113.
Stumvoll M., Goldstein B. J. & van Haeften T. W., Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005, 365, 1333-1346.
Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Society for the Study of Diabetes (EASD), Guidelines on diabetes, prediabetes and cardiovascular diseases: executive summary. Eur. Heart J., 2007, 28, 88-136.
The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329, 977-986.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care, 2003, 26, 3160-3167.
UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
WHO Study Group, Prevention of diabetes mellitus: report of WHO study group. WHO Tech. Rep. Ser., 1994, 844, 1-100.
Zimmet P., Alberti K.G. & Shaw J., Global and societal implications of the diabetes epidemic. Nature, 2001, 414, 782-787.
